FOURIER (TIMI 59) / EBBINGHAUS

FOURIER (TIMI 59) was a double-blind, randomized, placebo-controlled, multicenter study assessing the Impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease.  EBBINGHAUS was a cognitive study of patients enrolled in the FOURIER trial.

MAIN RESULTS:
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

PRESENTATIONS

FOURIER Main Results (Sabatine, ACC 2017)
EBBINGHAUS Main Results (Giugliano, ACC 2017)
BWH Cardiovascular Grand Rounds 4-6-17 (Sabatine)
Maximum Intensity Statin (Sabatine, NLA 2017)
Achieved LDL-C (Giugliano, ESC 2017)
Stroke (Pederson, ESC 2017)
Diabetes (Sabatine, EASD 2017)
PAD (Bonaca, AHA 2017)
MI Subgroup (Sabatine, AHA 2017)
Total Events (Murphy, AHA 2017)
MI Size and Type (Wiviott, AHA 2017)
Risk Score (Bohula, AHA 2017)
Variability in Evolocumab (Qamar, ACC 2018)
Inflammatory and Cholestrol Risk (Bohula, ACC 2018)
Martin Hopkins LDL-C (Martin, NLA 2018)
Lp(a) in FOURIER (O’Donoghue, EAS 2018)
Age and Sex (Sever, ESC 2018)
FOURIER Cognition Poster (Gencer AHA 2019)
FOURIER Genetics (Marston AHA 2019)
FOURIER Recent MI Poster (Gencer AHA 2019)
Performance Of A Novel Genetic Risk Score To Identify Risk Of VTE In Patients With Cardiometabolic Disease (Marston, ACC 2020)
PCSK9 Inhibition And Aortic Stenosis In The FOURIER Trial (Bergmark, ACC 2020)
Efficacy of Lowering Low-Density Lipoprotein Cholesterol in Older Patients (Gencer, AHA 2020)
Relationship Between Baseline LDL-C and %LDL-C Reduction with Evolocumab in the FOURIER Trial (Marcusa, AHA 2020)
Reduction with Evolocumab in Complex Coronary Revascularization (Oyama, AHA 2020)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Cardiovascular Outcomes in Patients with Established Atherosclerosis and LDLR Loss of Function (Marston, AHA 2020)
Combining High-Sensitivity Troponin with the AHA/ACC Cholesterol Guidelines To Guide Evolocumab Therapy (Marston, AHA 2020)
Effects of Evolocumab in Patients with Prior Percutaneous Coronary Intervention (Furtado, AHA 2020)

PUBLICATIONS

Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease

Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials

Response by Marston et al to Letter Regarding Article, “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism”

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial

Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial

Cognition After Lowering LDL-Cholesterol With Evolocumab

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

Correctly understanding the diabetes data in FOURIER

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER

Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

Inflammatory and Cholesterol Risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)

Clinical benefits of evolocumab appear less than hoped – Authors’ reply

Questioning the safety and benefits of evolocumab – Authors’ reply

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Cognitive Function in a Randomized Trial of Evolocumab

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial